Profile: UCB - Pharma Inc. focuses on severe diseases in three therapeutic areas such as CNS, inflammation and oncology. We specialize in the pharmaceutical industry. Our Keppra® (levetiracetam) is indicated for the treatment of several types of epilepsy including add-on treatment for adults and children from 4 years of age with partial onset seizures. Our Vimpat® (lacosamide) is indicated for the adjunctive treatment of partial onset seizures with or without secondary generalization in patients with epilepsy. Our Nootropil® (piracetam) is a cerebral function regulator, used to treat adults and the elderly.

The company has revenues of < USD 1 Million, has ~800 employees and is ISO 9000 certified.